OverviewSuggest Edit

BioAtla is a biopharmaceutical company that develops drugs for cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer.
TypePublic
Founded2007
HQSan Diego, CA, US
Websitebioatla.com

Latest Updates

Employees (est.) (Dec 2020)36
Revenue (FY, 2019)$5.2 M(-51%)
Share Price (May 2022)$2.3(+2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at BioAtla

Jay Short

Jay Short

Chairman, Chief Executive Officer & Cofounder
William Boyle

William Boyle

Chief Science Officer and VP Translational Medicine
Scott Smith

Scott Smith

President, Director
Richard Waldron

Richard Waldron

Chief Financial Officer
Eric Sievers

Eric Sievers

Chief Medical Officer
Monica Sullivan

Monica Sullivan

Vice President of Intellectual Property & Contracts
Show more

BioAtla Office Locations

BioAtla has an office in San Diego
San Diego, CA, US (HQ)
11085 Torreyana Rd
Show all (1)

BioAtla Financials and Metrics

BioAtla Revenue

BioAtla's revenue was reported to be $5.2 m in FY, 2019 which is a 51.1% decrease from the previous period.
USD

Revenue (FY, 2019)

5.2m

Revenue growth (FY, 2018 - FY, 2019), %

(51.1%)

Net income (FY, 2019)

(29.8m)

EBIT (FY, 2019)

(28.3m)

Market capitalization (20-May-2022)

85.1m

Closing stock price (20-May-2022)

2.3

Cash (30-Sept-2020)

56.8m

EV

29.0m
BioAtla's current market capitalization is $85.1 m.
USDFY, 2018FY, 2019

Revenue

10.6m5.2m

Revenue growth, %

(51%)

General and administrative expense

12.6m7.5m

R&D expense

26.3m25.9m
Annual
USDFY, 2018FY, 2019

Cash

10.9m3.7m

Current Assets

12.7m4.5m

PP&E

3.9m4.7m

Total Assets

16.6m9.3m
Quarterly
USDQ3, 2020

Cash

56.8m

Current Assets

57.5m

PP&E

4.0m

Total Assets

62.8m
Annual
USDFY, 2018FY, 2019

Net Income

(29.0m)(29.9m)

Depreciation and Amortization

794.0k860.0k

Accounts Payable

446.0k3.1m

Cash From Operating Activities

(35.3m)(9.6m)
Quarterly
USDQ3, 2019Q3, 2020

Net Income

(28.5m)(19.5m)

Depreciation and Amortization

1.7m716.0k

Accounts Payable

(7.7m)(1.3m)

Cash From Operating Activities

(22.3m)(22.3m)
USDFY, 2018

Debt/Equity

-0.1 x

Debt/Assets

0.2 x

Financial Leverage

-0.6 x
Show all financial metrics

BioAtla Operating Metrics

Q3, 2020

Discovery Stage Products

2

IND-Enabling Stage Products

3

Phase II Trials Products

2
Show all operating metrics

BioAtla Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

BioAtla Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

BioAtla Online and Social Media Presence

Embed Graph

BioAtla News and Updates

BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress

– Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma –

BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022

SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and other protein therapeutics, today announced that it plans to host a conference call and webcast o…

BioAtla Announces Pricing of Initial Public Offering

SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the pricing of its initial...

BioAtla Frequently Asked Questions

  • When was BioAtla founded?

    BioAtla was founded in 2007.

  • Who are BioAtla key executives?

    BioAtla's key executives are Jay Short, William Boyle and Scott Smith.

  • How many employees does BioAtla have?

    BioAtla has 36 employees.

  • What is BioAtla revenue?

    Latest BioAtla annual revenue is $5.2 m.

  • What is BioAtla revenue per employee?

    Latest BioAtla revenue per employee is $144.4 k.

  • Who are BioAtla competitors?

    Competitors of BioAtla include DAVA Oncology, Luye Pharma and Dragonfly.

  • Where is BioAtla headquarters?

    BioAtla headquarters is located at 11085 Torreyana Rd, San Diego.

  • Where are BioAtla offices?

    BioAtla has an office in San Diego.

  • How many offices does BioAtla have?

    BioAtla has 1 office.